Deferral of Influenza Vaccination During Moderate‑to‑Severe Acute Illness

Criteria for Deferral

• The American Academy of Pediatrics recommends postponing influenza vaccination in patients who have a moderate‑to‑severe febrile illness (e.g., high fever, active infection, or need for hospitalization) until the illness resolves, with the decision left to clinician judgment. 1
• The Centers for Disease Control and Prevention (CDC) advises that vaccination should be deferred when the patient has confirmed influenza A infection presenting with moderate‑to‑severe symptoms, because the active disease can impair the ability to mount an optimal antibody response. 1

Vaccination During Minor Illness

• Minor illnesses, including mild upper‑respiratory‑tract infection symptoms or allergic rhinitis, do not constitute a contraindication to influenza vaccination; vaccination may proceed in ambulatory patients with low‑grade or no fever. [1][2]
• The distinction between minor and moderate‑to‑severe illness is critical: when systemic illness is not significant, the vaccine can be administered without expected loss of efficacy. 1

Rationale for Deferral

• The CDC highlights that the primary reason for deferral is to avoid misattributing post‑vaccination respiratory symptoms to the vaccine rather than to the underlying illness, thereby preserving diagnostic clarity. 2
• Deferring vaccination also aims to optimize the immune response, as the immune system engaged in fighting an active influenza A infection may have reduced capacity to generate a robust response to the vaccine antigen. 1

Post‑Recovery Vaccination

• After clinical recovery from an acute influenza A infection, the AAP states that there is no required waiting period before administering the influenza vaccine; immunization can be performed immediately once symptoms have resolved. 1

Practical Decision‑Making Algorithm (AAP Guidance)

All statements are derived from cited sources and reflect the current recommendations of the American Academy of Pediatrics and the Centers for Disease Control and Prevention.

Influenza Vaccine Administration Guidelines

Key Safety Principles

• The influenza vaccine contains only noninfectious viruses and cannot cause influenza, as stated by the Centers for Disease Control and Prevention 3, 4, 5, 6
• Any respiratory illness occurring after vaccination represents either coincidental illness unrelated to vaccination or pre-existing infection that was incubating at the time of vaccination, according to the Centers for Disease Control and Prevention 3, 4, 5

Vaccination Timing

• It is usually preferable to delay vaccination of adults with acute febrile illnesses until their symptoms have abated, as recommended by the Centers for Disease Control and Prevention 3, 4, 5
• Minor illnesses with or without fever should not contraindicate the use of influenza vaccine, particularly among children with a mild upper respiratory tract infection or allergic rhinitis, as stated by the American Academy of Pediatrics and the Centers for Disease Control and Prevention 3, 4, 5, 7

Post-Infection Vaccination

• There is no required waiting period after influenza infection before administering the vaccine—only that the person has clinically recovered from the acute illness, according to the Centers for Disease Control and Prevention 8

Vaccine Safety and Efficacy

• No harm will occur from the vaccine itself, and the vaccine will not worsen the current infection, as stated by the Centers for Disease Control and Prevention 3, 4, 5
• The vaccine causes local reactions in 10-64% of recipients and occasional systemic symptoms (fever, malaise, myalgia) beginning 6-12 hours post-vaccination, but these are self-limited and distinct from influenza infection, according to the Centers for Disease Control and Prevention 6, 9